Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
| Autor: | Martin Svaton, Renata Chloupková, Lenka Jakubíková, Milada Zemanova, Juraj Kultan, František Salajka, Bohuslav Melichar, Vitezslav Kolek, Alzbeta Bejckova, Marek Konecny, Michal Hrnčiarik, Leona Koubková, Jana Skrickova, Miloš Pešek, David Vrána |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms 03 medical and health sciences 0302 clinical medicine Risk Factors Carcinoma Non-Small-Cell Lung Internal medicine Humans Medicine Progression-free survival Lung cancer Aged Retrospective Studies Inflammation Predictive marker business.industry Cancer Retrospective cohort study General Medicine Middle Aged Prognosis medicine.disease Survival Analysis 3. Good health Nivolumab 030104 developmental biology 030220 oncology & carcinogenesis Chronic Disease Absolute neutrophil count Biomarker (medicine) Female business |
| Zdroj: | Anticancer Research. 38:6771-6782 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | Aim To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and methods A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. Results Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. Conclusion Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|